CCL

Összesen 11 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM070110
Első szerző:Altenberger, Johann
Cím:Levosimendan in acute and advanced heart failure : an appraisal of the clinical database and evaluation of its therapeutic applications / Altenberger J., Gustafsson F., Harjola Veli-Pekka, Karason K., Kindgen-Milles D., Kivikko M., Malfatto G., Papp Z., Parissis J., Pollesello P., Pölzl G., Tschöpe C.
Dátum:2018
ISSN:0160-2446
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal Of Cardiovascular Pharmacology. - 71 : 3 (2018), p. 129-136. -
További szerzők:Gustafsson, Finn Harjola, Veli-Pekka Karason, Kristian Kindgen-Milles, D. Kivikko, Matti Malfatto, Gabriella Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Pollesello, Piero Pölzl, Gerhard Tschöpe, Carsten
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM076735
Első szerző:Bouchez, Stefan
Cím:Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application / S. Bouchez, F. Fedele, G. Giannakoulas, F. Gustafsson, Veli-Pekka Harjola, K. Karason, M. Kivikko, D. von Lewinski, F. Oliva, Z. Papp, J. Parissis, Piero Pollesello, G. Pölzl, C. Tschöpe
Dátum:2018
ISSN:0920-3206
Megjegyzések:Levosimendan, a calcium sensitizer and potassium channel-opener, is widely appreciated by many specialist heart failure practitioners for its effects on systemic and pulmonary hemodynamics and for the relief of symptoms of acute heart failure. The drug's impact on mortality in large randomized controlled trials has been inconsistent or inconclusive but, in contrast to conventional inotropes, there have been no indications of worsened survival and some signals of improved heart failure-related quality of life. For this reason, levosimendan has been proposed as a safer inodilator option than traditional agents in settings, such as advanced heart failure. Positive effects of levosimendan on renal function have also been described. At the HEART FAILURE 2018 congress of the Heart Failure Association of the European Society of Cardiology, safe and effective use levosimendan in acute and advanced heart failure was examined in a series of expert tutorials. The proceedings of those tutorials are summarized in this review, with special reference to advanced heart failure and heart failure with concomitant renal dysfunction. Meta-analysis of clinical trials data is supportive of a renal-protective effect of levosimendan, while physiological observations suggest that this effect is exerted at least in part via organ-specific effects that may include selective vasodilation of glomerular afferent arterioles and increased renal blood flow, with no compromise of renal oxygenation. These lines of evidence require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Inodilators
Inotropes
Acute heart failure
Advanced heart failure
Levosimendan
Renal function
Megjelenés:Cardiovascular Drugs And Therapy. - 32 : 6 (2018), p. 617-624. -
További szerzők:Fedele, Francesco Giannakoulas, George Gustafsson, Finn Harjola, Veli-Pekka Karason, Kristian Kivikko, Matti von Lewinski, Dirk Oliva, Fabrizio Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Pollesello, Piero Pölzl, Gerhard Tschöpe, Carsten
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM069431
Első szerző:Farmakis, Dimitrios
Cím:Levosimendan beyond inotropy and acute heart failure : evidence of pleiotropic effects on the heart and other organs : an expert panel position paper / Farmakis Dimitrios, Alvarez Julian, Gal Tuvia Ben, Brito Dulce, Fedele Francesco, Fonseca Candida, Gordon Anthony C., Gotsman Israel, Grossini Elena, Guarracino Fabio, Harjola Veli-Pekka, Hellman Yaron, Heunks Leo, Ivancan Visnja, Karavidas Apostolos, Kivikko Matti, Lomivorotov Vladimir, Longrois Dan, Masip Josep, Metra Marco, Morelli Andrea, Nikolaou Maria, Papp Zoltán, Parkhomenko Alexander, Poelzl Gerhard, Pollesello Piero, Ravn Hanne Berg, Rex Steffen, Riha Hynek, Ricksten Sven-Erik, Schwinger Robert H. G., Vrtovec Bojan, Yilmaz M. Birhan, Zielinska Marzenna, Parissis John
Dátum:2016
ISSN:0167-5273
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:International Journal Of Cardiology 222 (2016), p. 303-312. -
További szerzők:Alvarez, Julian Gal, Tuvia Ben Brito, Dulce Fedele, Francesco Fonseca, Candida Gordon, Anthony C. Gotsman, Israel Grossini, Elena Guarracino, Fabio Harjola, Veli-Pekka Hellman, Yaron Heunks, Leo Ivancan, Visnja Karavidas, Apostolos Kivikko, Matti Lomivorotov, Vladimir Longrois, Dan Masip, Josep Metra, Marco Morelli, Andrea Nikolaou, Maria Papp Zoltán (1965-) (kardiológus, élettanász) Parkhomenko, Alexander Poelzl, Gerhard Pollesello, Piero Ravn, Hanne Berg Rex, Steffen Riha, Hynek Ricksten, Sven-Erik Schwinger, Robert H. G. Vrtovec, Bojan Yilmaz, Mehmet Birhan Zielinska, Marzenna Parissis, John
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM090857
035-os BibID:(Scopus)85074122669
Első szerző:Harjola, Veli-Pekka
Cím:Use of levosimendan in acute heart failure / Harjola Veli-Pekka, Giannakoulas George, von Lewinski Dirk, Matskeplishvili Simon, Mebazaa Alexandre, Papp Zoltan, Schwinger Robert H. G., Pollesello Piero, Parissis John T.
Dátum:2018
ISSN:1520-765X
Megjegyzések:As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF). Other factors favouring levosimendan in this setting include its extended duration of action due to the formation of an active metabolite and the lack of any attenuation of effect in patients treated with beta-blockers. Effects of levosimendan on systemic haemodynamics include its significant, dose-dependent increases in cardiac output, stroke volume and heart rate, and decreases in right and left ventricular filling and total peripheral resistance. Rapid and sustained reduction in levels of natriuretic peptides is a consistent effect of levosimendan use and potentially favourable effects on other neurohormonal indicators of cardiac distress are also observed. Levosimendan has repeatedly been shown to be effective in relief of symptoms of AHF, notably dyspnoea and fatigue, while mortality data from clinical trials and registries suggest that levosimendan is markedly less likely than catecholaminergic inotropes to worsen prognosis. The vasodilator pharmacology of levosimendan is also pertinent to the drug's use in AHF, in which setting organ under-perfusion is often a key pathology. These considerations suggest that levosimendan may have a more favourable impact on the circumstances of the majority of AHF patients than adrenergic agents that act only or primarily as cardiac stimulants. They also suggest that levosimendan may advantageously be integrated into a comprehensive strategy of early intervention designed and intended to prevent cardiac destabilization worsening to the point where hospitalization is necessary. Levosimendan should be used with caution and with tightened haemodynamic monitoring in patients who have low baseline blood pressure (systolic blood pressure <100?mmHg; diastolic blood pressure <60?mmHg), or who are at risk of a hypotensive episode.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Heart Journal Supplements. - 20 : suppl. 1. (2018), p. I2-I10. -
További szerzők:Giannakoulas, George von Lewinski, Dirk Matskeplishvili, Simon Mebazaa, Alexandre Papp Zoltán (1965-) (kardiológus, élettanász) Schwinger, Robert H. G. Pollesello, Piero Parissis, John
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM070104
035-os BibID:(Wos)000405571400002 (Scopus)85020004824
Első szerző:Harjola, Veli-Pekka
Cím:Organ dysfunction, injury and failure in acute heart failure : from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) / Harjola Veli-Pekka, Mullens Wilfried, Banaszewski Marek, Bauersachs Johann, Brunner-La Rocca Hans-Peter, Chioncel Ovidiu, Collins Sean P., Doehner Wolfram, Filippatos Gerasimos S., Flammer Andreas J., Fuhrmann Valentin, Lainscak Mitja, Lassus Johan, Legrand Matthieu, Masip Josep, Mueller Christian, Papp Zoltán, Parissis John, Platz Elke, Rudiger Alain, Ruschitzka Frank, Schäfer Andreas, Seferovic Petar M., Skouri Hadi, Yilmaz Mehmet Birhan, Mebazaa Alexandre
Dátum:2017
ISSN:1388-9842
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Heart Failure. - 19 : 7 (2017), p. 821-836. -
További szerzők:Mullens, Wilfried Banaszewski, Marek Bauersachs, Johann Brunner-La Rocca, Hans-Peter Chioncel, Ovidiu Collins, Sean P. Doehner, Wolfram Filippatos, Gerasimos S. Flammer, Andreas J. Fuhrmann, Valentin Lainscak, Mitja Lassus, Johan Legrand, Matthieu Masip, Josep Mueller, Christian Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Platz, Elke Rudiger, Alain Ruschitzka, Frank Schäfer, Andreas Seferović, Petar M. Skouri, Hadi Yilmaz, Mehmet Birhan Mebazaa, Alexandre
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM090883
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero
Dátum:2020
ISSN:0160-2446
Megjegyzések:Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal Of Cardiovascular Pharmacology. - 76 : 1 (2020), p. 4-22. -
További szerzők:Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
   Lásd még:
Egyéb kapcsolat (1)
Borító:

7.

001-es BibID:BIBFORM090869
035-os BibID:(cikkazonosító)e19
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan Efficacy and Safety : 20 years of SIMDAX in Clinical Use / Papp Zoltán, Agostoni Piergiuseppe, Alvarez Julian, Bettex Dominique, Bouchez Stefan, Brito Dulce, Černý Vladimir, Comin-Colet Josep, Crespo-Leiro Marisa G., Delgado Juan F., Édes Istvan, Eremenko Alexander A., Farmakis Dimitrios, Fedele Francesco, Fonseca Cândida, Fruhwald Sonja, Girardis Massimo, Guarracino Fabio, Harjola Veli-Pekka, Heringlake Matthias, Herpain Antoine, Heunks Leo M. A., Husebye Trygve, Ivancan Višnja, Karason Kristjan, Kaul Sundeep, Kivikko Matti, Kubica Janek, Masip Josep, Matskeplishvili Simon, Mebazaa Alexandre, Nieminen Markku S., Oliva Fabrizio, Papp Julius-Gyula, Parissis John, Parkhomenko Alexander, Põder Pentti, Pölzl Gerhard, Reinecke Alexander, Ricksten Sven-Erik, Riha Hynek, Rudiger Alain, Sarapohja Toni, Schwinger Robert H. G., Toller Wolfgang, Tritapepe Luigi, Tschöpe Carsten, Wikström Gerhard, von Lewinski Dirk, Vrtovec Bojan, Pollesello Piero
Dátum:2020
Megjelenés:Utánközlés / Másodközlés
ISSN:2057-7540 2057-7559
Megjegyzések:Levosimendan was first approved for clinic use in 2000, when authorisation was granted by Swedish regulatory authorities for the haemodynamic stabilisation of patients with acutely decompensated chronic heart failure. In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitisation and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced heart failure, right ventricular failure and pulmonary hypertension, cardiac surgery, critical care and emergency medicine. Levosimendan is currently in active clinical evaluation in the US. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and non-cardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, UK and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute heart failure arena in recent times and charts a possible development trajectory for the next 20 years.
Papp Zoltán (1965-) (kardiológus, élettanász): Levosimendan Efficacy and Safety : 20 Years of SIMDAX in Clinical Use
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Cardiac Failure Review. - 6 (2020), p. 1-16. -
További szerzők:Agostoni, Piergiuseppe Alvarez, Julian Bettex, Dominique Bouchez, Stefan Brito, Dulce Cerny, Vladimir Comin-Colet, Josep Crespo-Leiro, Maria G. Delgado, Juan F. Édes István (1952-) (kardiológus) Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Fruhwald, Sonja Girardis, Massimo Guarracino, Fabio Harjola, Veli-Pekka Heringlake, Matthias Herpain, Antoine Heunks, Leo M. A. Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kivikko, Matti Kubica, Janek Masip, Josep Matskeplishvili, Simon Mebazaa, Alexandre Nieminen, Markku S. Oliva, Fabrizio Papp Gy. Julius (Szeged) Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Reinecke, Alexander Ricksten, Sven-Erik Riha, Hynek Rudiger, Alain Sarapohja, Toni Schwinger, Robert H. G. Toller, Wolfgang Tritapepe, Luigi Tschöpe, Carsten Wikström, Gerhard von Lewinski, Dirk Vrtovec, Bojan Pollesello, Piero
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
   Lásd még:
Utánközlés (1)
Borító:

8.

001-es BibID:BIBFORM040618
Első szerző:Papp Zoltán (kardiológus, élettanász)
Cím:Levosimendan : molecular mechanisms and clinical implications Consensus of experts on the mechanisms of action of levosimendan / Papp Z., Édes I., Fruhwald S., De Hert S. G., Salmenperä M., Leppikangas H., Mebazaa A., Landoni G., Grossini E., Caimmi P., Morelli A., Guarracino F., Schwinger R. H., Meyer S., Algotsson L., Wikström B. G., Jörgensen K., Filippatos G., Parissis J. T., González M. J., Parkhomenko A., Yilmaz M. B., Kivikko M., Pollesello P., Follath F.
Dátum:2012
Megjegyzések:The molecular background of the Ca(2+)-sensitizing effect of levosimendan relates to its specific interaction with the Ca(2+)-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K(+) channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K(+) channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:International Journal of Cardiology. - 159 : 2 (2012), p. 82-87. -
További szerzők:Édes István (1952-) (kardiológus) Fruhwald, Sonja De Hert, Stefan G. Salmenperä, Markku Leppikangas, Heli Mebazaa, Alexandre Landoni, Giovanni Grossini, Elena Caimmi, Philippe Morelli, Andrea Guarracino, Fabio Schwinger, Robert H. G. Meyer, Sven Algotsson, Lars Wikström, Gerhard Jörgensen, Kirsten Filippatos, Gerasimos S. Parissis, John González, Martín J. Parkhomenko, Alexander Yilmaz, Mehmet Birhan Kivikko, Matti Pollesello, Piero Follath Ferenc
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

9.

001-es BibID:BIBFORM081810
035-os BibID:(cikkazonosító)1834 (WoS)000502294400077 (Scopus)85091254940 (PMID)31683969
Első szerző:Pollesello, Piero
Cím:Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline? / Piero Pollesello, Tuvia Ben Gal, Dominique Bettex, Vladimir Cerny, Josep Comin-Colet, Alexandr A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Veli-Pekka Harjola, Antoine Herpain, Matthias Heringlake, Leo Heunks, Trygve Husebye, Visnja Ivancan, Kristian Karason, Sundeep Kaul, Jacek Kubica, Alexandre Mebazaa, Henning Mølgaard, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Bojan Vrtovec, Mehmet B. Yilmaz, Zoltan Papp
Dátum:2019
ISSN:2077-0383
Megjegyzések:Both acute and advanced heart failure are an increasing threat in term of survival, quality of life and socio-economical burdens. Paradoxically, the use of successful treatments for chronic heart failure can prolong life but-per definition-causes the rise in age of patients experiencing acute decompensations, since nothing at the moment helps avoiding an acute or final stage in the elderly population. To complicate the picture, acute heart failure syndromes are a collection of symptoms, signs and markers, with different aetiologies and different courses, also due to overlapping morbidities and to the plethora of chronic medications. The palette of cardio- and vasoactive drugs used in the hospitalization phase to stabilize the patient's hemodynamic is scarce and even scarcer is the evidence for the agents commonly used in the practice (e.g. catecholamines). The pipeline in this field is poor and the clinical development chronically unsuccessful. Recent set backs in expected clinical trials for new agents in acute heart failure (AHF) (omecamtiv, serelaxine, ularitide) left a field desolately empty, where only few drugs have been approved for clinical use, for example, levosimendan and nesiritide. In this consensus opinion paper, experts from 26 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, The Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, Turkey, U.K. and Ukraine) analyse the situation in details also by help of artificial intelligence applied to bibliographic searches, try to distil some lesson-learned to avoid that future projects would make the same mistakes as in the past and recommend how to lead a successful development project in this field in dire need of new agents.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
acute heart failure
advanced heart failure
clinical development
levosimendan
regulatory clinical trials
short-term hemodynamic therapy
Megjelenés:Journal of Clinical Medicine. - 8 : 11 (2019), p. 1-18. -
További szerzők:Ben Gal, Tuvia Bettex, Dominique Cerny, Vladimir Comin-Colet, Josep Eremenko, Alexandr A. Farmakis, Dimitrios Fedele, Francesco Fonseca, Candida Harjola, Veli-Pekka Herpain, Antoine Heringlake, Matthias Heunks, Leo Husebye, Trygve Ivancan, Visnja Karason, Kristian Kaul, Sundeep Kubica, Jacek Mebazaa, Alexandre Mølgaard, Henning Parissis, John Parkhomenko, Alexander Põder, Pentti Pölzl, Gerhard Vrtovec, Bojan Yilmaz, Mehmet Birhan Papp Zoltán (1965-) (kardiológus, élettanász)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM070112
Első szerző:Seferović, Petar M.
Cím:Organization of heart failure management in European Society of Cardiology member countries : survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups / Seferović Petar M., Stoerk Stefan, Filippatos Gerasimos, Mareev Viacheslav, Kavoliuniene Ausra, Ristić Arsen D., Ponikowski Piotr, McMurray John, Maggioni Aldol, Ruschitzka Frankl, van Veldhuisen Dirk J., Coats Andrew, Piepoli Massimo, McDonagh Theresa, Riley Jillian, Hoes Arno, Pieske Burkert, Dobrić Milan, Papp Zoltan, Mebazaa Alexandre, Parissis John, Ben Gal Tuvia, Vinereanu Dragos, Brito Dulce, Altenberger Johann, Gatzov Plamen, Milinković Ivan, Hradec Jaromír, Trochu Jean-Noel, Amir Offer, Moura Brenda, Lainscak Mitja, Comin Josep, Wikström Gerhard, Anker Stefan, Committee of National Heart Failure Societies or Working Groups of the Heart Failure Association of the European Society of Cardiology
Dátum:2013
ISSN:1388-9842
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Heart Failure. - 15 : 9 (2013), p. 947-959. -
További szerzők:Stoerk, Stefan Filippatos, Gerasimos S. Mareev, Vyacheslev Kavoliuniene, Ausra Ristić, Arsen D. Ponikowski, Piotr McMurray, John J. Maggioni, Aldo Ruschitzka, Frank van Veldhuisen, Dirk J. Coats, Andrew Piepoli, Massimo McDonagh, Theresa Riley, Jillian Hoes, Arno Pieske, Burkert Dobrić, Milan Papp Zoltán (1965-) (kardiológus, élettanász) Mebazaa, Alexandre Parissis, John Ben Gal, Tuvia Vinereanu, Dragos Brito, Dulce Altenberger, Johann Gatzov, Plamen Milinković, Ivan Hradec, Jaromír Trochu, Jean-Noel Amir, Offer Moura, Brenda Lainscak, Mitja Comin-Colet, Josep Wikström, Gerhard Anker, Stefan D. Committee of NHFS or WGHFA of the ESC
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM082736
035-os BibID:(PMID)30957868 (WoS)000490139300015 (Scopus)85068687380
Első szerző:Triposkiadis, Filippos
Cím:The continuous heart failure spectrum : moving beyond an ejection fraction classification / Filippos Triposkiadis, Javed Butler, Francois M. Abboud, Paul W. Armstrong, Stamatis Adamopoulos, John J. Atherton, Johannes Backs, Johann Bauersachs, Daniel Burkhoff, Robert O. Bonow, Vijay K. Chopra, Rudolf A. de Boer, Leon de Windt, Nazha Hamdani, Gerd Hasenfuss, Stephane Heymans, Jean-Sébastien Hulot, Marvin Konstam, Richard T. Lee, Wolfgang A. Linke, Ida G. Lunde, Alexander R. Lyon, Christoph Maack, Douglas L. Mann, Alexandre Mebazaa, Robert J. Mentz, Petros Nihoyannopoulos, Zoltan Papp, John Parissis, Thierry Pedrazzini, Giuseppe Rosano, Jean Rouleau, Petar M. Seferovic, Ajay M. Shah, Randall C. Starling, Carlo G. Tocchetti, Jean-Noel Trochu, Thomas Thum, Faiez Zannad, Dirk L. Brutsaert, Vincent F. Segers, Gilles W. De Keulenaer
Dátum:2019
ISSN:0195-668X
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Heart Journal. - 40 : 26 (2019), p. 2155-2163. -
További szerzők:Butler, Javed Abboud, Francois M. Armstrong, Paul W. Adamopoulos, Stamatis Atherton, John J. Backs, Johannes Bauersachs, Johann Burkhoff, Daniel Bonow, Robert O. Chopra, Vijay K. Boer, Rudolf A. de Windt, Leon de Hamdani, Nazha Hasenfuß, Gerd Heymans, Stephane Hulot, Jean-Sébastien Konstam, Marvin Lee, Richard T. Linke, Wolfgang A. Lunde, Ida G. Lyon, Alexander Maack, Christoph Mann, Douglas L. Mebazaa, Alexandre Mentz, Robert J. Nihoyannopoulos, Petros Papp Zoltán (1965-) (kardiológus, élettanász) Parissis, John Pedrazzini, Thierry Rosano, Giuseppe M. C. Rouleau, Jean-Lucien Seferović, Petar M. Shah, Ajay M. Starling, Randall C. Tocchetti, Carlo G. Trochu, Jean-Noel Thum, Thomas Zannad, Faiez Brutsaert, Dirk L. Segers, Vincent F. De Keulenaer, Gilles
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1